Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer

Acta Pharmacologica Sinica

Volumn 37, Issue 9, 2016, Pages 1237-1250

  Zhao, Yu Qian ^a   Yin, Yi Qiong ^b   Liu, Jie ^b   Wang, Gui Hua ^a   Huang, Jian ^a   Zhu, Ling Juan ^a   Wang, Jin Hui ^a,c  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SHIHEZI UNIVERSITY   (China)

Author keywords

apoptosis; autophagy; breast cancer; chlorpromazine; HJ PI01; lienal polypeptide; MDA MB 231 cells; PI003; Pim 2 inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; HJ PI01; PIM 2 INHIBITOR; POLYPEPTIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; HJ-PI01; ONCOPROTEIN; OXAZINE DERIVATIVE; PIM2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL LINE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; SIMULATION; SYNTHESIS; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; GENETICS; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MOLECULAR DYNAMICS; NUDE MOUSE; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; OXAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84984893004     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2016.60     Document Type: Article

References (39)

1. Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev 2014; 34: 136-59.
2. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11: 23-34.
3. Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol 2013; 85: 629-43.
4. Liu JJ, Lin M, Yu JY, Liu B, Bao JK. Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett 2011; 300: 105-14.
5. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997; 15: 1133-41.
6. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007; 98: 321-8.
7. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, Malott SR, et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006; 59: 285-8.
8. Cohen AM, Grinblat B, Bessler H, Kristt D, Kremer A, Schwartz A, et al. Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2004; 45: 951-5.
9. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001; 2: 167-79.
10. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009; 114: 4150-7.
11. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A 1989; 86: 8857-61.
12. Uddin N, Kim RK, Yoo KC, Kim YH, Cui YH, Kim IG, et al. Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer. Cancer Sci 2015; 106: 718-25.
13. Fu LL, Yang Y, Xu HL, Cheng Y, Wen X, Ouyang L, et al. Identification of novel caspase/autophagy-related gene switch to cell fate decisions in breast cancers. Cell Prolif 2013; 46: 67-75.
14. Agrawal S, Koschmieder S, Bäumer N, Reddy NG, Berdel WE, Müller-Tidow C, et al. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation. Leukemia 2008; 22: 78-86.
15. Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008; 111: 3751-9.
16. Mizuki M, Ueda S, Matsumura I, Ishiko J, Schwäble J, Serve H, et al. Oncogenic receptor tyrosine kinase in leukemia. Cell Mol Biol (Noisyle-grand) 2003; 49: 907-22.
17. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res 2006; 66: 3828-35.
18. Chen Y, Fu LL, Wen X, Liu B, Huang J, Wang JH, et al. Oncogenic and tumor suppressive roles of micro RNAs in apoptosis and autophagy. Apoptosis 2014; 19: 1177-89.
19. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of pim- 2, a new common proviral insertion site, in progression of lymphomas. EMBO J 1989; 8: 743-8.
20. Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, et al. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One 2009; 4: e7112.
21. Hanusova V, Skalova L, Kralova V, Matouskova P. Potential anti-cancer drugs commonly used for other indications. Curr Cancer Drug Targets 2015; 15: 35-52.
22. Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res 2007; 67: 11359-67.
23. Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis 2013; 34: 2080-9.
24. Liu Z, He W, Gao J, Luo J, Huang X, Gao C. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer. Oncotarget 2015; 6: 8019-35.
25. Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 2013; 29: 845-54.
26. Schuttelkopf AW, van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 2004; 60: 1355-63.
27. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol 2013; 66: 512-6.
28. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105: 4477-83.
29. Xue L, Fletcher GC, Tolkovsky AM. Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. Mol Cell Neurosci 1999; 14: 180-98.
30. Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A 2006; 103: 4952-7.
31. Liu B, Wen X, Cheng Y. Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis 2013; 4: e892.
32. Pierre F, Stefan E, Nédellec AS, Chevrel MC, Regan CF, Siddiqui-Jain A, et al. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett 2011; 21: 6687-92.
33. Dwyer MP, Keertikar K, Paruch K, Alvarez C, Labroli M, Poker C, et al. Discovery of pyrazolo[1,5-a]pyrimidine-based Pim inhibitors: a template-based approach. Bioorg Med Chem Lett 2013; 23: 6178-82.
34. Dakin LA, Block MH, Chen H, Code E, Dowling JE, Feng X, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 2012; 22: 4599-604.
35. Haddach M, Michaux J, Schwaebe MK, Pierre F, O'Brien SE, Borsan C, et al. Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor. ACS Med Chem Lett 2012; 3: 135-9.
36. Garcia PD, Langowski JL, Wang Y, Chen M, Castillo J, Fanton C, et al. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res 2014; 20: 1834-45.
37. Zavodszky E, Vicinanza M, Rubinsztein DC. Biology and trafficking of ATG9 and ATG16L1, two proteins that regulate autophagosome formation. FEBS Lett 2013; 587: 1988-96.
38. Chang NC, Nguyen M, Shore GC. BCL2-CISD2: An ER complex at the nexus of autophagy and calcium homeostasis? Autophagy 2012; 8: 856-7.
39. Jurin M, Zarković N, Ilić Z, Borović S, Hartleb M. Porcine splenic peptides (Polyerga) decrease the number of experimental lung metastases in mice. Clin Exp Metastasis 1996; 14: 55-60.